Bridgefront Capital’s Cue Biopharma CUE Stock Holding History

Bridgefront Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-666	Closed	-$50K	–	341
2022 Q2	$50K	Hold	666	–	–	0.06%	284
2022 Q1	$97K	Buy	+666	New	+$141K	0.12%	238

Other funds holding CUE

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bridgefront Capital's CUE Position: Q3 2022 in Review

Bridgefront Capital sold out of Cue Biopharma (CUE) in Q3 2022, closing a stake of 666 shares — an estimated $50K sold.

Bridgefront Capital first reported a position in CUE in Q1 2022 and held it in 2 quarters. The position peaked at $97K in Q1 2022. 64 funds tracked by Wall St. Rank hold CUE as of Q3 2022.

Bridgefront Capital reported no remaining Cue Biopharma position as of Q3 2022 after selling out during the quarter.
Bridgefront Capital sold 666 Cue Biopharma shares in Q3 2022, an estimated $50K.
Bridgefront Capital first reported a position in Cue Biopharma in Q1 2022 and held it in 2 quarters.
Bridgefront Capital's Cue Biopharma position peaked at $97K in Q1 2022.
64 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2022.

Based on Bridgefront Capital's 13F filing for Q3 2022, filed 29 Nov 2022.